BackgroundCheck.run
Search For

David H Stokoe, 5631 Rosewood Dr, San Francisco, CA 94127

Known as:
David Te Stokoe
Related to:
Francis C Delaney 66 John Kennedy Capp 60

David Stokoe Phones & Addresses

31 Rosewood Dr, San Francisco, CA 94127   

340 Fillmore St, San Francisco, CA 94117    415-8317273    415-8615844   

Colfax, CA   

Berkeley, CA   

Walnut Creek, CA   

Get Report
Control this profile

Mentions for David H Stokoe

David Stokoe resumes & CV records

Resumes

David Stokoe Photo 18

Principal Investigator

Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Calico
Principal Investigator Genentech Aug 2007 - Mar 2017
Senior Scientist University of Calfornia San Francisco Mar 1997 - Aug 2007
Associate Professor Onyx Pharmaceuticals Jan 1994 - Feb 1997
Postdoc
Education:
University of Bristol Law School 1987 - 1990
Skills:
Drug Discovery, Molecular Biology, Cell Biology, Biotechnology, Biochemistry, Assay Development, Protein Chemistry, Cancer, Cell Culture, Cell, Western Blotting, Elisa, Antibodies, Monoclonal Antibodies
David Stokoe Photo 19

David Stokoe

David Stokoe Photo 20

David Stokoe

David Stokoe Photo 21

David Stokoe

Publications & IP owners

Us Patents

Small Molecule Inhibition Of A Pdz-Domain Interaction

US Patent:
7141600, Nov 28, 2006
Filed:
Apr 15, 2004
Appl. No.:
10/826175
Inventors:
R. Kiplin Guy - Concord CA, US
Irwin D. Kuntz - Greenbrae CA, US
Jose Haresco - San Francisco CA, US
Naoaki Fujii - South San Francisco CA, US
Kathleen P. Novak - Watham MA, US
David Stokoe - San Francisco CA, US
Biao He - San Mateo CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/404
C07D 209/12
C07D 209/30
C07D 209/04
US Classification:
514415, 548491, 548490, 548469, 548465
Abstract:
Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formulaThe invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.

Small Molecule Inhibition Of A Pdz-Domain Interaction

US Patent:
7601750, Oct 13, 2009
Filed:
Oct 11, 2006
Appl. No.:
11/580001
Inventors:
R. Kiplin Guy - Concord CA, US
Irwin D. Kuntz - Greenbrae CA, US
Jose Haresco - San Francisco CA, US
Naoaki Fujii - South San Francisco CA, US
Kathleen P. Novak - Watham MA, US
David Stokoe - San Francisco CA, US
Biao He - South San Francisco CA, US
Liang You - San Francisco CA, US
Zhidong Xu - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/404
C07D 209/04
US Classification:
514415, 548509
Abstract:
Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formulaThe invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.

Compositions And Methods For Identifying Pkb Kinase Inhibitors

US Patent:
6682920, Jan 27, 2004
Filed:
Sep 17, 1998
Appl. No.:
09/156793
Inventors:
Len Stephens - Cambridge, GB
Philip Hawkins - Cambridge, GB
David Stokoe - San Francisco CA
Assignee:
Onyx Pharmaceuticals, Inc. - Richmond CA
International Classification:
C12N 912
US Classification:
435194, 435 691, 4352523, 4353201, 435 15, 536 232
Abstract:
Compositions and methods are described that are useful to assay for compouds that affect PKB kinase activity which have medical applications for the diagnosis and treatment of disease.

Methods For Diagnosing And Treating Cancer By Means Of The Expression Status And Mutational Status Of Nrf2 And Downstream Target Genes Of Said Gene

US Patent:
2019021, Jul 18, 2019
Filed:
Dec 21, 2018
Appl. No.:
16/230223
Inventors:
- South San Francisco CA, US
- Cambridge MA, US
David Hugh STOKOE - San Francisco CA, US
Robert GENTLEMAN - San Mateo CA, US
Florian GNAD - Boston MA, US
Leonard David GOLDSTEIN - Burlingame CA, US
Juliann CHMIELECKI - Medford MA, US
Ryan J. HARTMAIER - Cambridge MA, US
International Classification:
C12Q 1/6886
C12Q 1/6806
C12Q 1/686
C12Q 1/6872
A61P 35/00
A61K 31/337
Abstract:
The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.

Possible Relatives

James B Stokoe  Jennifer A Stokoe  Lisa S Stokoe  Andrew J Stokoe  David Last  David W Johnson  David Stamps  David L Stanard  David M Stanbery  David A Stanchfield 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.